BGB-43395 for Drug Interaction Study

This trial aims to determine if the new drug BGB-43395 affects how other common medications work in the body. Participants will take BGB-43395 with drugs like midazolam (used for sedation), celecoxib (a pain reliever), dabigatran (a blood thinner), and rosuvastatin (a cholesterol-lowering drug) to check for interactions. Those who are generally healthy and have no significant medical conditions might be suitable for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

Research has shown that BGB-43395 is generally safe. In earlier studies, about 94% of participants experienced side effects, but most were mild to moderate. This indicates the treatment is safe for most people. Severe reactions were not commonly reported, supporting its overall safety.¹²³⁴⁵

Researchers are excited about BGB-43395 because it explores how this new compound interacts with common medications like midazolam, celecoxib, dabigatran, and rosuvastatin. Unlike other treatments that are already established, BGB-43395 might offer a unique mechanism of action or improved safety profile when used in combination with these drugs. This study could reveal new insights into potential drug interactions, leading to safer and more effective medication regimens for patients who require these treatments.

Research has shown that BGB-43395 targets proteins involved in cell growth, which can slow or stop cancer cell growth. Studies have found that drugs like BGB-43395 effectively treat some cancers, especially breast cancer, by blocking proteins that allow cancer cells to multiply. In this trial, participants will receive BGB-43395 alongside other medications to study its interactions. Part 1 of the trial involves midazolam and celecoxib, while Part 2 involves dabigatran and rosuvastatin. Early results suggest BGB-43395 might work well with other cancer treatments, but more research is needed to confirm its safety and effectiveness.⁶⁷⁸⁹¹⁰